Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Dec 22, 2021 5:44am
182 Views
Post# 34253453

RE:RE:Recent CMO promotion/ announcement

RE:RE:Recent CMO promotion/ announcement

You are correct, but missed a very important piece of information.
Rita was quoted. As saying " a CMO will not be needed until phase 3 gets underway".
Back to my point, the promoted to CMO to fasilitate the phase 3 process.
At last cc, it was said..." we are ramping up towards phase 3 registration "
The CMO announcement is part of that.
you keep mentioning " to the moon" a phrase I have never used.
but since you have coined that phrase.
recall it took ample preparations and failures to get Appolo 9 to land o; the moon.
very little in scientific development happens first try & without many micro steps.
in an early Appolo mission. The very astronauts were burned. To death. During testing. 
it was sad, horrifying and tragic. But did not mean the end of the program.
even Appolo 8, which was the first ever manned orbit around the moon was ground breaking science.
There were BTW, naysayers back then. Pointing previous failures or the huge $$ or huge waste of time " we can never land o;the moon".
just like the Mercury missions & proceeding Appolo 1-8 had valuable information, lessons & failures.
ONC has its history.
The Bracelt & Aware-1 are the early pre trials of Phase 3.
I know this anology is well over some present day naysayers I.Q. 
for those who understand, thanks.
for those more curious.
please go to oncolytics biotec web & read up. Tons of data.
recent " investor presentation " complies it well.
wishing all a Merry Christmas & happy 2022.
 

 

<< Previous
Bullboard Posts
Next >>